Equities research analysts expect Evolent Health Inc (NYSE:EVH) to announce ($0.11) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Evolent Health’s earnings, with estimates ranging from ($0.19) to ($0.03). Evolent Health posted earnings per share of ($0.26) in the same quarter last year, which suggests a positive year-over-year growth rate of 57.7%. The company is expected to report its next quarterly earnings results on Tuesday, August 4th.
According to Zacks, analysts expect that Evolent Health will report full year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.58) to ($0.15). For the next financial year, analysts forecast that the business will report earnings of ($0.37) per share, with EPS estimates ranging from ($1.19) to $0.04. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Evolent Health.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). Evolent Health had a negative return on equity of 6.09% and a negative net margin of 37.17%. The business had revenue of $247.29 million during the quarter, compared to analyst estimates of $239.35 million.
Shares of NYSE:EVH remained flat at $$7.40 during midday trading on Friday. 1,529,700 shares of the stock were exchanged, compared to its average volume of 1,415,754. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.09 and a quick ratio of 1.09. The firm has a fifty day moving average price of $7.04 and a two-hundred day moving average price of $7.90. Evolent Health has a 1 year low of $3.50 and a 1 year high of $12.01. The firm has a market capitalization of $632.55 million, a price-to-earnings ratio of -1.87 and a beta of 1.68.
A number of large investors have recently bought and sold shares of EVH. State Street Corp raised its holdings in shares of Evolent Health by 19.6% during the first quarter. State Street Corp now owns 1,783,872 shares of the technology company’s stock valued at $9,686,000 after acquiring an additional 292,880 shares during the last quarter. Credit Suisse AG raised its stake in Evolent Health by 3.6% in the 4th quarter. Credit Suisse AG now owns 3,745,881 shares of the technology company’s stock valued at $33,900,000 after purchasing an additional 128,588 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Evolent Health by 149.6% in the 4th quarter. Bank of New York Mellon Corp now owns 1,609,737 shares of the technology company’s stock valued at $14,569,000 after purchasing an additional 964,723 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Evolent Health by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 459,908 shares of the technology company’s stock worth $4,163,000 after purchasing an additional 10,309 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Evolent Health by 10.9% during the first quarter. Two Sigma Investments LP now owns 271,486 shares of the technology company’s stock worth $1,474,000 after buying an additional 26,744 shares in the last quarter. Institutional investors own 93.03% of the company’s stock.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Story: Back-End Load
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.